[The activity of etoposide (VP16) in combination chemotherapy against human bladder cancer cells in vitro].
The activity of Etoposide (VP16) in combination chemotherapy against four human transitional cell carcinoma cell lines of bladder (TCCaB) was determined by in vitro colony formation assay. Four anti-tumor agents (methotrexate: MTX, vinblastine: VBL, adriamycin: ADM, cisplatin: DDP) were used for combination chemotherapy with VP16. The ADM + VP16 combination exhibited a strong synergistic antitumor effect against the human TCCaBs compared with other combinations in this study. The combination chemotherapy of ADM + VP16 may be useful as a new chemotherapeutic regimen for advanced bladder cancer.
Hattori
T
T
Department of Urology, Nippon Medical School.
Satoh
M
M
Terashima
Y
Y
Nishimura
T
T
Akimoto
M
M
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D002295:Carcinoma, Transitional Cell / Q000473:pathology*; D002945:Cisplatin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage*; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage; D014407:Tumor Cells, Cultured / Q000187:drug effects; D014410:Tumor Stem Cell Assay; D001749:Urinary Bladder Neoplasms / Q000473:pathology*; D014747:Vinblastine / Q000008:administration & dosage
D014747:Vinblastine; D005047:Etoposide; D004317:Doxorubicin; D002945:Cisplatin; D008727:Methotrexate